A Levitzki
Impact in
- Oncology top 2%
- Cytokine Signaling Pathways and Interactions
- HER2/EGFR in Cancer Research
- Hematology top 2%
- Chronic Myeloid Leukemia Treatments
Papers in
-
- Protein Kinase Regulation and GTPase Signaling 4
- PI3K/AKT/mTOR signaling in cancer 4
- Metabolism, Diabetes, and Cancer 2
- Oncology 7
- HER2/EGFR in Cancer Research 7
- Co-authors
- Aviv Gazit (15 shared papers)Chaim Gilon (5 shared papers)Amos Cohen (1 shared paper)Chaim M. Roifman (1 shared paper)Enrico Arpaia (1 shared paper)J. Steven Leeder (1 shared paper)Harjit Dadi (1 shared paper)Michal Shahar (1 shared paper)
- Journals
- Blood (2 papers)Molecular Pharmacology (2 papers)The EMBO Journal (2 papers)FEBS Letters (1 paper)Journal of Pharmacology and Experimental Therapeutics (1 paper)
- Partner nations
- IsraelUnited StatesFrance
In The Last Decade
A Levitzki
26 papers receiving 3.1k citations
A Levitzki's Hit Papers
Peers
Comparison fields: 5 of 106
- Oncology 1.1k
- Hematology 415
- Genetics 327
- Immunology and Allergy 173
- Molecular Biology 1.8k
Countries citing papers authored by A Levitzki
This map shows the geographic impact of A Levitzki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A Levitzki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A Levitzki more than expected).
Fields of papers citing papers by A Levitzki
This network shows the impact of papers produced by A Levitzki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A Levitzki. The network helps show where A Levitzki may publish in the future.
Co-authors
The 25 scholars most cited alongside A Levitzki, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 27 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor Hit paper breakdown → | 1996 | 816 |
| 2 | 1999 | 371 | |
| 3 | Flk-1 as a target for tumor growth inhibition. | 1996 | 293 |
| 4 | 1992 | 291 | |
| 5 | 1989 | 274 | |
| 6 | 1999 | 196 | |
| 7 | 1993 | 118 | |
| 8 | 1991 | 109 | |
| 9 | 2001 | 81 | |
| 10 | Enhancement of chemosensitivity by tyrphostin AG825 in high-p185(neu) expressing non-small cell lung cancer cells. | 1996 | 78 |
| 11 | 2004 | 72 | |
| 12 | Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia. | 1994 | 71 |
| 13 | 1994 | 61 | |
| 14 | 1989 | 56 | |
| 15 | 1996 | 51 | |
| 16 | 1998 | 42 | |
| 17 | Signal therapy for RAS-induced cancers in combination of AG 879 and PP1, specific inhibitors for ErbB2 and Src family kinases, that block PAK activation. | 2001 | 42 |
| 18 | 1992 | 37 | |
| 19 | 1994 | 26 | |
| 20 | 2004 | 26 |
About A Levitzki
A Levitzki is a scholar working on Molecular Biology, Oncology, Radiology, Nuclear Medicine and Imaging, Ecology, Evolution, Behavior and Systematics and Hematology, having authored 27 papers that have together received 3.2k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (7 papers), Monoclonal and Polyclonal Antibodies Research (4 papers), Protein Kinase Regulation and GTPase Signaling (4 papers), Fungal Plant Pathogen Control (4 papers), Chronic Myeloid Leukemia Treatments (4 papers), PI3K/AKT/mTOR signaling in cancer (4 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Metabolism, Diabetes, and Cancer (2 papers). The work is most often cited by research in Oncology (1.1k citations), Hematology (415 citations), Genetics (327 citations), Immunology and Allergy (173 citations) and Molecular Biology (1.8k citations). A Levitzki has collaborated with scholars based in Israel, United States and France. Frequent co-authors include Aviv Gazit, Chaim Gilon, Amos Cohen, Chaim M. Roifman, Enrico Arpaia, J. Steven Leeder, Harjit Dadi, Michal Shahar, Melvin H. Freedman and John Kuriyan. Their work appears in journals such as Blood, Molecular Pharmacology, The EMBO Journal, FEBS Letters and Journal of Pharmacology and Experimental Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.